Document is current
Any future updates will be listed below
-
Authors
Williams, Charles H.
Neitzel, Leif R.
Cornell, Jessica
Rea, Samantha
Mills, Ian
Silver, Maya S.
Ahmad, Jovanni D.
Birukov, Konstantin G.
Birukova, Anna
Brem, Henry
Tyler, Betty
Bar, Eli E.
Hong, Charles C.
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (R01GM118557, R01GM118557, R01GM118557)
TEDCO (MII0521-0010, MII0521-0010, MII0521-0010, MII0521-0010)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR007592-26)
- License Information
-
More Information
Article History
Received: 14 December 2023
Accepted: 25 December 2023
First Online: 31 January 2024
Declarations
:
: The University Committee on Use and Care of Animals at the University of Maryland, Baltimore, approved all animal protocols. All animal protocols conformed to the <i>Guiding Principles in the Care and Use of Animals</i>.
: CHW and CCH are inventors on an issued patent related to this manuscript. HB is a paid consultant to InSightec and chairman of the company’s Medical Advisory Board. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict-of-interest policies. HB receives research funding from NIH, Johns Hopkins University, and philanthropy. He is a consultant for CraniUS, Candel Therapeutics, Inc., InSightec*, Accelerating Combination Therapies*, Catalio Nexus Fund II, LLC*, LikeMinds, Inc*, Galen Robotics, Inc.* and Nurami Medical*. BT has research funding from NIH and is a co-owner for Accelerating Combination Therapies*. Ashvattha Therapeutics Inc. and a stockholder for Peabody Pharmaceuticals (*includes equity or options).
